“This new trivalent vaccine provides a strong immune foundation, optimises protection for flocks and offers reliable protection,” said Matt Nelson, head of Boehringer Ingelheim Animal Health’s US poultry business.
The three-in-one vaccine is the latest addition in the VAXXITEK family of vaccines for poultry. It uses the same bioengineering platform as VAXXITEK HVT+IBD, which has protected more than 100 billion birds from Marek’s Disease and Infectious Bursal Disease in more than 75 countries since its introduction in 2006.
Infectious Laryngotracheitis (ILT) is an acute viral respiratory disease caused by Gallid herpesvirus type 1 in poultry. There is no effective treatment for ILT, and the virus persists for life in affected birds. The disease can cause significant economic losses.
Boehringer Ingelheim Animal Health’s existing non-vectored vaccine protects against ILT. The new trivalent vaccine is a vectored vaccine that protects ILT along with two other health threats to poultry: Marek’s Disease and Infectious Bursal Disease.
The company will manufacture its new vaccine in Gainesville, Georgia, where it produces 60 billion doses of poultry vaccine per year for use in the US and around 60 other countries.
After launching in the US, Boehringer Ingelheim Animal Health plans to seek regulatory approval to offer VAXXITEK HVT+IBD+ILT in other countries.